RTOG-3505 Cisplatin and Etoposide + Radiation Prior to Nivolumab/Placebo for Local Advanced NSCLC

Grants and Contracts Details


HUMAN CLINICAL TRIAL Randomized, Double Blinded Phase III Trial of Cisplatin and Etoposide plus Thoracic Radiation Therapy Followed by Nivolumab/Placebo for Unresectable Locally Advanced Non-Small Cell Lung Cancer Primary Objective • To compare the overall snrvival (OS) for patients with Stage III nmesectable nonsmall lung cancer treated with or without nivolumab following concurrent chemoradiation.
Effective start/end date1/11/1711/28/18


  • RTOG Foundation Incorporated: $15,800.00


Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.